NY-ESO-1 Peptide vaccine for Stage III Ovarian Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
MedStar Georgetown University Hospital, Washington, United States
Stage III Ovarian Cancer+3 More
NY-ESO-1 Peptide vaccine - Biological
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This is an open label, non-randomized, 2-stage phase II, single arm study to determine the efficacy of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide vaccine as a priming mechanism to prevent anti-PD1 resistance in patients with platinum-refractory stage III/IV ovarian cancer (OC).

Eligible Conditions

  • Stage III Ovarian Cancer
  • Advanced Ovarian Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 2 years

2 years
Disease Control Rate
Duration of Response
Incidence of Adverse Events (AE)
Median Overall Survival
Median Progression Free Survival
Overall Response Rate

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

NY-ESO-1 Peptide vaccine plus Nivolumab
1 of 1
Experimental Treatment

24 Total Participants · 1 Treatment Group

Primary Treatment: NY-ESO-1 Peptide vaccine · No Placebo Group · Phase 2

NY-ESO-1 Peptide vaccine plus NivolumabExperimental Group · 2 Interventions: NY-ESO-1 Peptide vaccine, Nivolumab · Intervention Types: Biological, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nivolumab
2014
Completed Phase 3
~5540

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
Closest Location: MedStar Georgetown University Hospital · Washington, United States
Photo of washington  1Photo of washington  2Photo of washington  3
2010First Recorded Clinical Trial
1 TrialsResearching Stage III Ovarian Cancer
99 CompletedClinical Trials

Eligibility Criteria

Age 18+ · Female Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Imaging of target lesion(s) within 28 days prior to registration.
You are free of active infection requiring antibiotics.
You have received radiation therapy to the head, neck, or chest.
You have had major surgery in the last 4 weeks.
You are able and willing to provide written and signed informed consent prior to performing any protocol-related procedures, including screening evaluations.
You are not taking any hormonal therapy directed at the malignant tumor.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.